Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 27;13(5):868–878. doi: 10.21037/tau-23-541

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2024 Translational Andrology and Urology. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Imaging results at diagnosis and through the course of treatment. FDG PET-CT (A) and PSMA PET-CT (B) whole-body scans showing the comparison of the metabolically active metastases before (on the left) and after 6 cycles of chemotherapy with an addition of GnRH antagonist (on the right). FDG PET-CT (C,D) and PSMA PET-CT (E,F) scans with concomitant CT scans: at the diagnosis (C,E) and re-staging after 6 cycles of chemotherapy with etoposide/carboplatin with an addition of GnRH antagonist (D,F). FDG PET-CT, fluorodeoxyglucose positron emission tomography-computed tomography; PSMA, prostate-specific membrane antigen; GnRH, gonadotrophin-releasing hormone.